Format

Send to

Choose Destination
Pharmacogenomics. 2019 Jan 10. doi: 10.2217/pgs-2018-0140. [Epub ahead of print]

Genetic variation of kinases and activation of nucleotide analog reverse transcriptase inhibitor tenofovir.

Author information

1
Department of Medicine (Division of Clinical Pharmacology), Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Abstract

As antiretroviral therapy has become more accessible across the world and coformulations have improved patient compliance; the morbidity and mortality of HIV/AIDS has decreased. However, there is still a substantial gap in knowledge regarding the impact of genetic variation on the metabolism of and response to some of the most commonly prescribed antiretrovirals, including the nucleotide reverse transcriptase inhibitor tenofovir. While it has been scientifically established that tenofovir must be activated to be efficacious against HIV, the enzymes responsible for this activation have not been well characterized. The purpose of this review is to summarize and clarify the scientific knowledge regarding the enzymes that phosphorylate and activate this clinically important drug.

KEYWORDS:

HIV; antiretroviral therapy; drug metabolism; genetic variants; precision medicine

PMID:
30628547
DOI:
10.2217/pgs-2018-0140

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center